Janssen, Sinopharm and Sputnik V vaccines are less effective against Omicron: study

The vaccines against Covid-19 from the US pharmaceutical Johnson & Johnson and from china Sinopharmas well as the Russian Sputnik V, did not have neutralizing activity against Omicron variantaccording to a study that is not yet peer-reviewed.

The Omicron variant it has raised concerns about its ability to circumvent the protection offered by widely used vaccines and has prompted drug manufacturers to tailor their vaccines to attack it, while testing the efficacy of their existing injections.

The vaccines from Moderna, AstraZeneca and Pfizer and their partner BioNTech were active against Omicron, but the response of the antibodies It was significantly reduced compared to the original strain of the virus first detected in China, according to the research.

The study, conducted by Humabs Biomed SA, a unit of Vir Biotechnology and the University of Washington, among others, also found that the decline was less pronounced in vaccinated individuals who were previously infected.

The study also found that, while the efficacy of the drug sotrovimab against Covid-19 in GlaxoSmithKline y Vir Biotech was reduced three times in front of Omicron Compared to the parent strain, the Regeneron and Eli Lilly monoclonal antibody treatments completely lost their neutralizing activity against the variant.

The finding is consistent with recent laboratory tests showing that the two treatments lose most of their efficacy when exposed to the omicron variant.

In a real-world study published this week, Pfizer-BioNTech’s COVID-19 vaccine was found to have been less effective in South Africa in preventing hospitalization of people infected with the virus since the variant appeared. omicron last month.


Leave a Comment